Recombinant Macaca mulatta Gonadotropin-releasing hormone II receptor (GNRHR2) (S367R, D373G)

What is GNRHR2 and how does it differ from GNRHR1?

GNRHR2 is the receptor for gonadotropin-releasing hormone II (GnRH II). It mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system . Unlike GNRHR1 which primarily regulates pituitary gonadotropin secretion, GNRHR2 has a broader distribution and more diverse functions.

The type II GnRH receptor has only 41% sequence identity with the type I receptor, suggesting an early evolutionary gene duplication . A critical structural difference is that GNRHR2 possesses a carboxyl-terminal tail, which is important for rapid desensitization and is uniquely absent from mammalian type I receptors . Additionally, GNRHR2 does not have the unusual Asn/Asp microdomain of transmembrane helices 2 and 7 found in mammalian type I receptors, instead having the Asp/Asp motif as in non-mammalian type I GnRH receptors .

What is the significance of studying Macaca mulatta GNRHR2 specifically?

Macaca mulatta (Rhesus macaque) expresses a functional full-length GNRHR2, unlike humans where GNRHR2 exists as a pseudogene with frameshift mutations and premature stop codons . This makes the Rhesus macaque receptor an invaluable model for studying the functional properties of type II GnRH receptors that can then be extrapolated to understand potential functions in humans.

The marmoset type II receptor amino acid sequence is 80% identical to the partial human type II receptor sequence, suggesting evolutionary conservation of this receptor system despite the pseudogenization in humans . Using the Macaca mulatta GNRHR2 allows researchers to investigate signaling pathways and physiological roles that might be relevant to human reproductive biology and pathology.

What is the binding specificity of GNRHR2 for its ligands?

GNRHR2 demonstrates high selectivity for GnRH II over GnRH I, as illustrated in the following comparative data:

This data shows that GnRH II is 100- to 400-fold more active at GNRHR2 than GnRH I, while GnRH I is only approximately 10-fold more active at GNRHR1 than GnRH II . This receptor selectivity is critical for understanding the distinct physiological roles of these signaling systems.

Interestingly, certain GNRHR1 antagonists (e.g., antagonist 135-18) act as agonists at GNRHR2 , highlighting the pharmacological differences between these receptor subtypes.

What are recommended methodological approaches for studying GNRHR2 activation and signaling?

Based on established research protocols, the following experimental approaches are recommended:

• Receptor binding assays: To characterize ligand-receptor interactions using radiolabeled ligands (e.g., 125I-labeled GnRH2) .

• Inositol phosphate accumulation assays: To measure receptor activation via Gαq/11 coupling and phospholipase C activation .

• MAP kinase activation assays: To monitor ERK1/2 and p38 MAPK phosphorylation using Western blotting or phospho-specific ELISA .

• Cell proliferation assays: Thymidine incorporation into DNA to monitor antiproliferative effects over time .

• Apoptosis assays: Monitoring cleavage of poly(ADP-ribose)polymerase (PARP), a substrate of caspase 3, to assess pro-apoptotic effects .

• In vivo tumor growth models: Using nude mice bearing tumors of cell lines expressing the receptor to evaluate antitumor effects of GNRHR2 ligands .

These methodologies provide complementary approaches to understanding the multifaceted functions of GNRHR2 signaling.

How should researchers handle and store the recombinant GNRHR2 protein for optimal stability?

For optimal stability and activity of the recombinant protein:

• Store lyophilized protein at -20°C/-80°C

• After reconstitution, aliquot to avoid repeated freeze-thaw cycles

• The shelf life of lyophilized form is approximately 12 months at -20°C/-80°C

• The shelf life of liquid form is approximately 6 months at -20°C/-80°C

• Reconstitute in deionized sterile water to a concentration of 0.1-1.0 mg/mL

• Add 5-50% glycerol (final concentration) for long-term storage

• Working aliquots can be stored at 4°C for up to one week

The stability of the protein depends on multiple factors including buffer composition, storage temperature, and the intrinsic stability of the protein itself .

How do the signaling pathways activated by GNRHR2 differ from those activated by GNRHR1?

GNRHR2 activates distinct signaling pathways compared to GNRHR1, which explains their different physiological effects:

• Common pathways: Both receptors couple to Gαq/11 and activate the phosphatidylinositol-calcium second messenger system .

• Differential MAPK activation:

  • Both receptors activate extracellular signal-regulated kinase (ERK1/2)

  • GNRHR2 uniquely activates p38 mitogen-activated protein kinase (MAPK), which GNRHR1 does not

  • The time course of p38α activation through GNRHR2 is more protracted than ERK2 activation

  • Neither receptor appears to activate c-Jun N-terminal kinase (JNK)

• Antiproliferative signaling: The activation of p38 MAPK by GNRHR2 may contribute to its antiproliferative effects, as this pathway is known to inhibit cell proliferation .

This differential signaling is significant because it leads to distinct physiological outcomes, with GNRHR2 activation more strongly associated with antiproliferative and potentially pro-apoptotic effects compared to GNRHR1.

What is ligand-induced selective signaling (LiSS) in the context of GNRHR2?

Ligand-induced selective signaling (LiSS) refers to the phenomenon where different ligands binding to the same receptor preferentially activate different downstream signaling pathways . For GNRHR2, this means:

• Different GnRH analogs can selectively activate certain signaling cascades over others.

• This selectivity explains why GnRH II is more potent than GnRH I in inhibiting cell growth while being less potent in stimulating gonadotropin secretion .

• Certain GnRH I antagonists (e.g., antagonist 135-18) can act as agonists at GNRHR2, selectively activating some but not all signaling pathways .

• Structure-activity relationship studies have shown that specific amino acid substitutions in GnRH analogs can create highly selective compounds with differential effects on cell proliferation versus inositol phosphate production .

Understanding LiSS provides opportunities to develop selective therapeutic agents that target specific GNRHR2-mediated functions while minimizing unwanted effects.

How does the expression and function of GNRHR2 vary across species?

GNRHR2 shows significant variation in expression and functionality across species:

This evolutionary divergence suggests different selective pressures on GNRHR2 function across species and possibly the development of alternative mechanisms in species that lack a functional receptor.

What hypotheses exist for the potential functionality of GNRHR2 in humans despite its pseudogene status?

Several hypotheses have been proposed to explain how the human GNRHR2 gene might retain functionality despite appearing to be a pseudogene:

• Counteractive shifts in the reading frame: Some human GNRHR2 transcripts have been isolated missing the stop codon .

• Alternative start codon: A GUG codon downstream of the frameshift could serve as an alternative start codon, yielding a 5-TM receptor with a truncated N-terminus (22 amino acids). This GUG codon meets the Kozak criteria necessary for an alternative start codon .

• Recoding of stop codons: The premature stop codon might be recoded, a phenomenon that occurs in mammals .

• Alternative splicing: Different splice variants might bypass the problematic regions.

• Functionality of GNRHR2 fragments: Truncated receptor fragments might retain some functionality .

Experimental evidence supporting these hypotheses includes the detection of a 43-kDa protein (corresponding to a 5-TM GNRHR2) in human endometrial cancer cells that specifically binds GnRH2 . This suggests that despite its pseudogene status, some form of GNRHR2 might be expressed and functional in humans.

How does the antiproliferative activity of GNRHR2 relate to potential cancer therapeutics?

The antiproliferative and pro-apoptotic effects of GNRHR2 activation make it a promising target for cancer therapeutics:

• Mechanism of action: GnRH II is more potent than GnRH I in inhibiting cell growth and inducing apoptosis in various cancer cell lines . This effect is mediated through GNRHR2 and involves activation of p38 MAPK, which is known to be antiproliferative .

• Expression in cancer tissues: GNRHR2 is expressed in various reproductive cancers (prostate, ovarian, and mammary gland tumors) , providing a target for therapy.

• Pharmacological considerations:

  • In HEK293 cells expressing rat GNRHR, GnRH II decreased thymidine incorporation more effectively than GnRH I

  • GnRH II induced apoptosis (measured by PARP cleavage) more rapidly (24h) than GnRH I (48h)

  • In nude mice bearing tumors, d-amino acid stabilized analogs of GnRH II (d-Lys6 and d-Arg6) effectively stopped or regressed tumor growth, while native GnRH II was ineffective due to rapid degradation

• Dual action potential: Some GnRH analogs can simultaneously inhibit cancer cell growth directly through GNRHR2 and reduce gonadal steroid production through GNRHR1 effects on gonadotropins .

These findings highlight the potential for developing selective GNRHR2 agonists as novel cancer therapeutics with potentially fewer side effects than current hormonal treatments.

What are the considerations for developing selective ligands for GNRHR2?

Developing selective ligands for GNRHR2 requires understanding several key factors:

• Structure-activity relationship: The three amino acids that differ between GnRH I and GnRH II (His5, Trp7, and Tyr8 in GnRH II) are critical for selectivity :

  • His5 replacement of Tyr5 in GnRH I produced the highest increase in antiproliferative potency

  • Tyr8 substitution of Arg8 produced the most selective analog, with very poor inositol phosphate generation but high antiproliferative potency

• Stability considerations: Native GnRH peptides are rapidly degraded in vivo. d-amino acid substitutions (particularly at position 6) protect against degradation and significantly enhance in vivo efficacy .

• Antagonist/agonist confusion: Some GNRHR1 antagonists (e.g., antagonist 135-18) act as agonists at GNRHR2 , which complicates pharmacological studies but might offer therapeutic opportunities.

• Receptor binding domains: The VPPS sequence in extracellular loop 3 (EC3) of GNRHR2 differs from the LSD/EP sequence in GNRHR1 and is likely important for ligand selectivity .

• Receptor conformational states: Molecular modeling suggests different contact points for GnRH I and GnRH II with the human GnRH receptor. Arg8 of GnRH I makes contact with Asp302, whereas Tyr8 of GnRH II appears to make different contacts, suggesting these residues stabilize different receptor conformations .

These considerations provide a foundation for rational drug design targeting GNRHR2 for various therapeutic applications, particularly in reproductive cancers.